Evercore Says Impeachment Step May Hurt Drug-Price Deal, USMCA
This article is for subscribers only.
An impeachment process is “an enormous undertaking” that’s likely to make any U.S. policy accomplishments hard to come by, according to Evercore ISI.
House Speaker Nancy Pelosi said on Tuesday that the House is opening a formal impeachment inquiry of President Donald Trump, asserting that he’s violated his oath of office and obligations under the Constitution. Legislation on pharmaceutical prices is one aspect of the agenda that’s likely to be hindered by the development, Sarah Bianchi, Evercore ISI’s head of U.S. public policy, wrote in a note Tuesday.